• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Screening for hypercholesterolemia among Canadians: how much will it cost?对加拿大人进行高胆固醇血症筛查:成本几何?
CMAJ. 1991 Jan 15;144(2):161-8.
2
[The lowering of serum cholesterol in the prevention of coronary disease (part 1). The Canadian Study Group for Periodic Medical Examinations].[血清胆固醇降低在冠心病预防中的作用(第1部分)。加拿大定期体检研究组]
Union Med Can. 1994 Apr;123(4):249-58.
3
A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.老年人血脂水平与冠心病的长期随访研究
Chin Med J (Engl). 2004 Feb;117(2):163-7.
4
The cost of implementation of the Clinical Laboratory Improvement Amendments of 1988--the example of pediatric office-based cholesterol screening.1988年《临床实验室改进修正案》的实施成本——以儿科门诊胆固醇筛查为例。
Pediatrics. 1995 Aug;96(2 Pt 1):230-4.
5
Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.加拿大人群中高血浆甘油三酯合并低高密度脂蛋白胆固醇水平的患病率及其与吸烟、高血压、肥胖、糖尿病、久坐不动和低密度脂蛋白胆固醇水平的关联。加拿大心脏健康调查研究小组。
Can J Cardiol. 1999 Apr;15(4):428-33.
6
Cardiovascular risk factors and lipoprotein profile in French Canadians with premature CAD: impact of the National Cholesterol Education Program II.患有早发性冠心病的法裔加拿大人的心血管危险因素和脂蛋白谱:国家胆固醇教育计划II的影响
Can J Cardiol. 1995 Feb;11(2):109-16.
7
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.已确诊冠心病或风险等同情况且低密度脂蛋白胆固醇得到控制的患者中低高密度脂蛋白胆固醇的患病率。
Am J Cardiol. 2007 Nov 15;100(10):1499-501. doi: 10.1016/j.amjcard.2007.06.058. Epub 2007 Sep 27.
8
Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey.评估韩国成年人冠心病的风险因素及其风险预测:2001年韩国国家健康与营养检查调查
Int J Cardiol. 2006 Jun 16;110(2):184-90. doi: 10.1016/j.ijcard.2005.07.030. Epub 2006 Jan 18.
9
Cost-effectiveness of nurse practitioner management of hypercholesterolemia following coronary revascularization.冠状动脉血运重建术后执业护士管理高胆固醇血症的成本效益
J Am Acad Nurse Pract. 2006 Sep;18(9):436-44. doi: 10.1111/j.1745-7599.2006.00159.x.
10
Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.基于模型的模拟,以探讨遵循糖尿病和混合性血脂异常患者甘油三酯和低密度脂蛋白胆固醇控制实践指南的成本效益。
Clin Ther. 2009 Apr;31(4):862-79. doi: 10.1016/j.clinthera.2009.04.015.

引用本文的文献

1
Resource utilisation in the management of dyslipidaemia.血脂异常管理中的资源利用
Pharmacoeconomics. 1998;14 Suppl 3:11-8. doi: 10.2165/00019053-199814003-00002.
2
Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.全科医疗中胆固醇相关干预措施的经济学评估。证据评估。
J Epidemiol Community Health. 1998 Sep;52(9):586-94. doi: 10.1136/jech.52.9.586.
3
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.辛伐他汀。对其在血脂异常和冠心病治疗中成本效益的重新评估。
Pharmacoeconomics. 1997 Jan;11(1):89-110. doi: 10.2165/00019053-199711010-00010.
4
Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.高胆固醇血症药物治疗的成本效益:文献综述
Pharmacoeconomics. 1992 Jul;2(1):34-42. doi: 10.2165/00019053-199202010-00005.
5
Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.辛伐他汀:对其在高胆固醇血症及冠心病预防中的成本效益进行的药物经济学评估。
Pharmacoeconomics. 1992 Feb;1(2):124-45. doi: 10.2165/00019053-199201020-00009.
6
Modifying serum lipids to prevent coronary heart disease: do we have a consensus?通过调节血脂来预防冠心病:我们达成共识了吗?
Cardiovasc Drugs Ther. 1993 Nov;7(5):761-5. doi: 10.1007/BF00878927.
7
Screening in the office for elevated cholesterol levels: still a dilemma.在办公室进行胆固醇水平升高的筛查:仍然是一个难题。
CMAJ. 1994 Jul 1;151(1):25-7.
8
Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study.医生能否准确评估患者的冠心病风险?冠心病健康评估研究的初步结果。
BMJ. 1995 Apr 15;310(6985):975-8. doi: 10.1136/bmj.310.6985.975.

本文引用的文献

1
Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study.血浆胆固醇和甘油三酯的再测信度。脂质研究临床患病率研究。
Am J Epidemiol. 1982 Dec;116(6):878-85. doi: 10.1093/oxfordjournals.aje.a113490.
2
Cholesterol reduction and life expectancy. A model incorporating multiple risk factors.胆固醇降低与预期寿命。一个纳入多种风险因素的模型。
Ann Intern Med. 1987 Apr;106(4):605-14. doi: 10.7326/0003-4819-106-4-605.
3
Cholesterol and mortality. 30 years of follow-up from the Framingham study.胆固醇与死亡率。来自弗雷明汉心脏研究的30年随访
JAMA. 1987 Apr 24;257(16):2176-80. doi: 10.1001/jama.257.16.2176.
4
Major risk factors for cardiovascular disease mortality in adults: results from the Nutrition Canada Survey cohort.成年人心血管疾病死亡的主要风险因素:加拿大营养调查队列研究结果
Int J Epidemiol. 1988 Jun;17(2):317-24. doi: 10.1093/ije/17.2.317.
5
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.赫尔辛基心脏研究:吉非贝齐用于中年血脂异常男性的一级预防试验。治疗安全性、危险因素变化及冠心病发病率
N Engl J Med. 1987 Nov 12;317(20):1237-45. doi: 10.1056/NEJM198711123172001.
6
The impact of preventive cardiology on coronary artery disease.预防心脏病学对冠状动脉疾病的影响。
CMAJ. 1988 Oct 15;139(8):719-24.
7
Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia.直击胆固醇。治疗高胆固醇血症的经济有效替代方案。
JAMA. 1988 Apr 15;259(15):2249-54. doi: 10.1001/jama.259.15.2249.
8
Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine.抗高血脂疗法在预防冠心病方面的成本效益。考来烯胺的案例。
JAMA. 1987 Nov 6;258(17):2381-7.
9
Cholesterol and risk of coronary heart disease and mortality in men.男性体内胆固醇与冠心病风险及死亡率
Clin Chem. 1988;34(8B):B53-9.
10
Hypercholesterolemia.高胆固醇血症
CMAJ. 1989 Jan 15;140(2):176.

对加拿大人进行高胆固醇血症筛查:成本几何?

Screening for hypercholesterolemia among Canadians: how much will it cost?

作者信息

Grover S A, Coupal L, Fahkry R, Suissa S

机构信息

Centre for Cardiovascular Risk Assessment, Montreal General Hospital, Que.

出版信息

CMAJ. 1991 Jan 15;144(2):161-8.

PMID:1986828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1453000/
Abstract

OBJECTIVE

To determine the cost of screening all Canadians aged 30 years or more without coronary heart disease (CHD) for hypercholesterolemia.

DATA SOURCES

The expected results of initial screening of the serum cholesterol level were estimated on the basis of 1986 Canadian census data and the 1978 Canada Health Survey. The results of repeat testing were estimated on the basis of data from the Lipid Research Clinics Prevalence Study. Lipid profile results were extrapolated from tests at the Montreal General Hospital's clinical chemistry laboratory. Laboratory costs and primary care practitioner costs were provided by the Canadian Society of Clinical Chemists and provincial fee schedules respectively.

MAIN RESULTS

Among 12,479,356 Canadians free of CHD 48.7% would be identified as being at high risk, 4.8% would be identified as being at moderate risk, and 46.6% would be reassured that their lipid risk for CHD was low. The total cost of implementing the program in the first year would be $432 million to $561 million ($325 million for laboratory tests and $107 million to $236 million for visits to primary care practitioners).

CONCLUSION

The substantial cost of implementing a nationwide screening program must be weighed against the expected benefits to ensure that the final result is both practical and economically feasible.

摘要

目的

确定对所有30岁及以上无冠心病(CHD)的加拿大人进行高胆固醇血症筛查的成本。

数据来源

血清胆固醇水平初始筛查的预期结果是根据1986年加拿大人口普查数据和1978年加拿大健康调查估算得出的。重复检测的结果是根据脂质研究诊所患病率研究的数据估算得出的。血脂谱结果是从蒙特利尔综合医院临床化学实验室的检测结果推断而来的。实验室成本和初级保健医生成本分别由加拿大临床化学家协会和省级收费标准提供。

主要结果

在12479356名无冠心病的加拿大人中,48.7%将被确定为高危人群,4.8%将被确定为中度风险人群,46.6%将放心地得知其患冠心病的脂质风险较低。该项目第一年实施的总成本将在4.32亿加元至5.61亿加元之间(实验室检测费用为3.25亿加元,初级保健医生诊疗费用为1.07亿加元至2.36亿加元)。

结论

实施全国性筛查项目的巨大成本必须与预期收益相权衡,以确保最终结果既切实可行又在经济上可行。